Understand the source comparison
Epithalon vs Melatonin: Direct Comparison Table
The following table summarizes the key differences across mechanism, evidence, dosing, and practical considerations: Primary Mechanism Binds MT1/MT2 receptors in SCN; modulates circadian rhythm and acts as ROS scavenger Claimed to activate telomerase (hTERT ge
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table summarizes the key differences across mechanism, evidence, dosing, and practical considerations:
- Primary Mechanism
- Binds MT1/MT2 receptors in SCN; modulates circadian rhythm and acts as ROS scavenger
- Claimed to activate telomerase (hTERT gene) and extend telomeres; exact signaling pathway not fully elucidated
- Melatonin mechanism is well-characterized and reproducible. Epithalon mechanism supported in vitro but lacks broad independent validation
- Clinical Evidence Base
- Thousands of RCTs; meta-analyses confirm sleep onset and circadian phase-shifting effects
- Limited to Russian observational studies and animal models; minimal third-party replication in humans
- Melatonin has regulatory approval (e.g., EU, UK for pediatric insomnia). Epithalon remains investigational with no FDA approval
- Standard Dosing
- 0.5–5mg oral, 30–60 min before sleep or at fixed circadian time; daily use common
- 5–10mg subcutaneous injection per day for 10–20 days, cycled every 3–6 months
- Melatonin dosing is standardized. Epithalon dosing is empirical and varies by protocol
- Onset of Effect
- 20–60 minutes for sleep onset; circadian shift requires 3–7 days of consistent timing
- Telomerase activity increases within 24–48 hours in vitro; telomere elongation requires weeks to months
- Melatonin effects are acute and measurable within one night. Epithalon requires sustained exposure
- Route of Administration
- Oral (tablets, capsules, sublingual)
- Subcutaneous or intramuscular injection; cannot be taken orally
- Oral convenience favors melatonin for chronic use. Injection limits Epithalon to research settings
- Adverse Event Profile
- Daytime sedation at high doses; rare reports of vivid dreams, headache, dizziness
- Minimal reported AEs in published studies; injection site reactions possible; long-term human safety data limited
- Melatonin safety profile well-documented over decades. Epithalon safety extrapolated from animal studies
- Bottom Line
- Best suited for circadian rhythm disorders, sleep onset delay, jet lag, and antioxidant support
- Investigated for cellular senescence and longevity research; evidence insufficient for clinical recommendation outside research use
- Use melatonin for validated sleep and circadian applications. Consider Epithalon only in controlled research with outcome measurement